Otsuka
As of the edition of 20 October 2026, Otsuka runs 12 drugs, 4 of them marketed; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 9 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 3 |
| Went quiet | 2 |
| Stopped | 3 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tolvaptan | Ended 2026 (patent) | 0 |
| Rebamipide | none listed | 0 |
| Delamanid | none listed | 0 |
| Sibeprenlimab | Ends 2037 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Otsuka needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 5 trials led
- Digestive system: 4 trials led
- Skin and connective tissue: 4 trials led